SecBot SecBot
20-F ·Filed Aug 27, 2026

MESO

MESOBLAST LTD
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago SEC0001345099-26-000081
Notable filing: 20-F
Actionable Insight ▲ Bullish

The 20-F confirms Ryoncil's commercial ramp is real with $115M in first-year sales, and the $125M refinancing removes near-term liquidity risk. The key catalyst to watch is the mid-CY2027 CLBP Phase 3 readout, which could unlock a much larger market. Traders should monitor quarterly revenue growth and any pipeline updates (adult SR-aGvHD, DMD) for sustained momentum.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

MESO drug pipeline →

rexlemestrocel-L

▲ Bullish Named in this 20-F
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$18.18
T+0 close · Aug 27, 2026 · via day close
Latest settled
−14.85%
T+20 · $15.48 · next T+60 in 3d
Vs SPY
−14.34%
α at T+20
Latest observation
−22.43%
T+55 · FF3 residual α
  1. T+0 · Aug 27 $18.18entry
  2. T+1 · 3mo ago −4.07%α −3.84% · $17.44
  3. T+5 · 3mo ago −5.72%α −5.99% · $17.14
  4. T+20 · 8w ago −14.85%α −14.34% · $15.48
  5. T+56 · todayOpen
  6. T+60 · in 3d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast filed its annual 20-F for FY2026, reporting first full-year product revenue of $115.2M from Ryoncil (approved Dec 2024), a net loss of $57.5M, and cash of $102.9M. The company refinanced its debt with a $125M non-dilutive credit line at 8% interest, reducing borrowing costs. The filing confirms commercial launch progress and a strengthened balance sheet, but the company remains unprofitable with accumulated losses of $1.07B and faces ongoing clinical and regulatory risks for pipeline candidates like rexlemestrocel-L (CLBP, CHF). The cross-filing context amplifies the positive revenue trajectory and pipeline milestones (Phase 3 CLBP enrollment complete, adult SR-aGvHD trial started, DMD IND cleared). Overall, the annual report confirms a transition to a commercial-stage biotech with a validated product, but profitability is not yet achieved, warranting a neutral-to-bullish read with moderate impact.

Key Facts

  • Ryoncil net revenue was $115.2M for FY2026, the first full year post-FDA approval.
  • Net loss for FY2026 was $57.5M; accumulated deficit reached $1,068.4M.
  • Cash and cash equivalents were $102.9M as of June 30, 2026.
  • Entered a $125M five-year non-dilutive credit-line facility in Dec 2025, secured by TEMCELL royalties, at 8% fixed interest, used to extinguish Oaktree and NovaQuest debt.
  • Net cash used in operating activities was $43.8M for FY2026.
  • Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain enrolled target of 300 patients; top-line results expected mid-CY2027.
  • Adult SR-aGvHD label extension trial for Ryoncil commenced; IND cleared for Duchenne muscular dystrophy.
  • BLA filing number received for rexlemestrocel-L in LVAD patients; CAR technology license acquired.

Financial Impact

First full-year product revenue of $115.2M from Ryoncil; net loss of $57.5M; $102.9M cash; $125M new credit facility at 8% interest reduces debt cost.

revenuenet losscashdebt

Risk Factors

  • Company remains unprofitable with $1.07B accumulated deficit; profitability timeline uncertain.
  • Pipeline candidates (rexlemestrocel-L for CLBP, CHF) face binary Phase 3 readout risk; failure would reset valuation.
  • Reliance on single approved product (Ryoncil) for near-term revenue; any commercial setback would be material.
  • Foreign exchange risk from AUD/USD exposure on debt and operations.
  • Regulatory risks for label extensions and new indications; FDA may require additional trials.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
20-F Filing (Primary)0001345099-26-000081
Document: 0001345099-26-000081-index.html0001345099-26-000081
Document: 0001345099-26-000081.txt0001345099-26-000081

Track record

25 reports on MESO

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Viewing Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 27, 2026